CARAMBA

CARAMBA is a #H2020 research project evaluating safety and efficacy of #SLAMF7 specific #CARTcells treating #MultipleMyeloma patients.

[CARAMBA @CARAMBA_project]

On 30th of June 2023, the EU-funded project #CARAMBA is coming to an end, marking five years of challenges and successes in the mission to revolutionise #MultipleMyeloma treatment and beyond. Check out the press release: https://t.co/53zyVkGXGI

[CARAMBA @CARAMBA_project]

Get ready for the EHA/EBMT #CART2024 Meeting in Valencia, hosted by @CARAMBA_project coordinator Michael Hudecek and @AnnaSureda5 . Meet the pioneers incl. @H_Einsele and find out about therapy innovations in #MultipleMyeloma . Register now: https://t.co/eYofZguB64 🧬🔬

[Myeloma Patients Europe @MyelomaEurope]

Join us on 6 July 2023 from 17:00 - 18:00 CET for the MPE webinar about #EHA2023's most important #myeloma and #ALamyloidosis updates presented at the congress.

Click on the link to register: https://t.co/qCoCpf5wsr

@Mohty_EBMT

[European Hematology Association @EHA_Hematology]

In our latest podcast on #CART therapy, Prof. Hermann Einsele talks about the current landscapes of CAR-T therapy in myeloma, results achievable today, and future perspectives for patients.

Find it on major podcast platforms or the #EHACampus here:
https://t.co/Xp7Skqb2HU

[Myeloma Patients Europe @MyelomaEurope]

Check out the report and tools MPE has designed for the Minimal Residual Disease (MRD) research project that helps understand the patient and clinician experience and perspectives of #MRD.

Click on the link to explore: https://t.co/h9UhP6SbFA

[Dr. Felipe Prósper @FelipeProsper]

It was really a pleasure to share our work with our colleagues contributing to the development of CAR-T cell therapies in #Spain. Interesting session with many relevant questions and a great chair @JuanBueren

[Universitätsklinikum Würzburg @Uniklinikum_Wue]

CAR-T-Zell-Therapie mit einer Cilta-Cel-Infusion führt zu deutlich geringerem Risiko für ein Fortschreiten der Erkrankung #MultiplesMyelom oder den Tod im Vgl zur Standardtherapie. @H_Einsele: Hoffnung auf längere Krankheitsfreiheit und Heilungsoptionen durch frühe Anwendung.

[NEJM @NEJM]

Three patients with T-cell ALL were treated with allogeneic CAR T cells that were base-edited to prevent CAR T-cell fratricide and graft-versus-host disease and to evade lymphodepleting serotherapy. https://t.co/y2W8TN4Cmo

[Multiple Myeloma Hub @MM_Hub]

🚨 NEWS 🚨
@US_FDA authorize a phase Ib clinical trial of STAR-LLD for the treatment of multiple #myeloma.
STAR-LLD is an SQ continuous delivery lenalidomide that would replace oral lenalidomide combined with bortezomib and dexamethasone.
👉 https://t.co/w7irmscSNr
#mednews #mmsm

[Myeloma Patients Europe @MyelomaEurope]

Join us on 6 July 2023 from 17:00 - 18:00 CET for the MPE webinar about #EHA2023's most important #myeloma and #ALamyloidosis updates presented at the congress.

Click on the link to register: https://t.co/qCoCpf5wsr

[Myeloma Patients Europe @MyelomaEurope]

#EHA2023 ends today with great presentations and discussions about #myeloma and #ALamyloidosis. Thank you to amazing hematologists who responds our interviews and make EHA higlights easier to understand for patients! @Mohty_EBMT @mvmateos @H_Einsele #DrKastritis @MinnemaMonique

[European Hematology Association @EHA_Hematology]

Though the Hybrid Days have now ended, that doesn't mean #EHA2023 is over. From June 14-15, #EHA would like to invite our registered delegates back to the Congress Platform for our Virtual Days. View selected highlights below 👇
View the program: https://t.co/g8KgCQLUwx

[Myeloma Patients Europe @MyelomaEurope]

In 15 min Dr. Hermann Einsele will speak about the first phase 3 results from CARTITUDE-4 as part of the plenary abstract session at #EHA2023. Dr Einsele will summarise for MPE the main results of this presentation in an interview. Keep an eye out for our social media profiles!

[CARAMBA @CARAMBA_project]

Immune and disease monitoring in #MMyeloma. @BrunoPaiva_UNAV (@ClinicaNavarra) presents CTCs as powerful prognostic factor.

[CARAMBA @CARAMBA_project]

Virus-free #CART #GMP manufacturing in Europe. Halvard Bönig (@blutspende_de) summarizes CARAMBA experiences. It's all about T cell quality.

[CARAMBA @CARAMBA_project]

#CARAMBA_project coordinator Michael Hudecek (@Uniklinikum_Wue) welcomes all partners to the last General Assembly. What did we achieve? Which challenges we had to face? What were the patients' experiences? What's next? Follow-us this afternoon! @MyelomaEurope

[Multiple Myeloma Hub @MM_Hub]

One day to go!

💭What: The ins and outs of CAR T cells in the real world. An expert roundtable hosted by the Lymphoma Hub and the Multiple Myeloma Hub
📍Where: Frankfurt, Germany & Online
📅When: June 9 |16:15–17:45 CEST

Get involved for 1 credit of EBAH accreditation!

#mmsm

[CARAMBA @CARAMBA_project]

Back-to-back to #EHA2023 #CARAMBA_project will have it's 6th and last General Assembly. >5 five years of wonderful, enthusiastic and pioneering collaboration! Today we will discuss our final results. Looking forward to seeing you all in Frankfurt! @BrunoPaiva_UNAV @i_yakoub_agha

[European Hematology Association @EHA_Hematology]

Today the world of #hematology comes together for the first day of #EHA2023 in Frankfurt, Germany and online on the Congress Platform.

Catch up on the latest in basic research and career development at the #YoungEHA Research Meeting or follow the today's Satellite Symposia.

[Myeloma Patients Europe @MyelomaEurope]

If you are a patient receiving #CART therapy, share your experience in @t2evolve_imi's survey. The survey aims to improve quality of life in patients and their carers by learning from your insights.

Scan the QR code or read more here: https://t.co/RuXyYN6wBb